Recent discussions on X regarding DiaMedica Therapeutics (DMAC) have been buzzing with interest following news of significant insider buying and upcoming presentations at major healthcare conferences. Many users are highlighting a major shareholder's purchase of nearly $6 million in shares, viewing it as a strong signal of confidence in the company's future. The focus is also on DMAC's innovative treatments for conditions like preeclampsia and stroke, which are set to be showcased at events such as the Cantor Global Healthcare Conference.
Additionally, there’s a mix of curiosity and speculation about how these developments might impact the stock's trajectory, with some pointing to analyst targets suggesting significant upside potential. Posts on X reflect enthusiasm over the company’s clinical-stage advancements, though a few express caution due to a recent downgrade by a research firm to a 'sell' rating. This blend of optimism and wariness keeps the conversation dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
DiaMedica Therapeutics Insider Trading Activity
DiaMedica Therapeutics insiders have traded $DMAC stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $DMAC stock by insiders over the last 6 months:
- JAN STAHLBERG has made 10 purchases buying 2,542,857 shares for an estimated $11,358,106 and 0 sales.
- KOCH THOMAS VON purchased 2,857,142 shares for an estimated $9,999,997
- RICHARD II JACINTO purchased 400,000 shares for an estimated $1,400,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DiaMedica Therapeutics Hedge Fund Activity
We have seen 39 institutional investors add shares of DiaMedica Therapeutics stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,085,463 shares (+1020.7%) to their portfolio in Q2 2025, for an estimated $4,233,305
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 523,797 shares (-94.1%) from their portfolio in Q2 2025, for an estimated $2,042,808
- MILLENNIUM MANAGEMENT LLC removed 336,880 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,313,832
- GEODE CAPITAL MANAGEMENT, LLC added 314,407 shares (+99.6%) to their portfolio in Q2 2025, for an estimated $1,226,187
- VANGUARD GROUP INC added 183,587 shares (+13.6%) to their portfolio in Q2 2025, for an estimated $715,989
- STATE STREET CORP added 166,919 shares (+196.3%) to their portfolio in Q2 2025, for an estimated $650,984
- NORTHERN TRUST CORP added 147,258 shares (+83.1%) to their portfolio in Q2 2025, for an estimated $574,306
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DiaMedica Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $DMAC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/15/2025
- Craig-Hallum issued a "Buy" rating on 07/18/2025
- Lake Street issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for DiaMedica Therapeutics, check out Quiver Quantitative's $DMAC forecast page.
DiaMedica Therapeutics Price Targets
Multiple analysts have issued price targets for $DMAC recently. We have seen 3 analysts offer price targets for $DMAC in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $12.0 on 08/15/2025
- Chase Knickerbocker from Craig-Hallum set a target price of $11.0 on 07/18/2025
- Thomas Flaten from Lake Street set a target price of $14.0 on 07/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
